Figure 6

Uptake of [⁶⁴Cu]Cu-NOTA-B11-diabody in (A) B16-F10 PD-L1_KO cancer cells and B16-F10 hPD-L1+ cells and in (B) EO771 PD-L1_KO and hPD-L1 overexpressing EO771 hPD-L1+ cells. ^#p < 0.05 B16-F10 hPD-L1+ vs B16-F10 PD-L1_KO (n = 3), *p < 0.05 EO771 hPD-L1+ vs EO771 PD-L1_KO (n = 3).